JP2021519061A5 - - Google Patents

Info

Publication number
JP2021519061A5
JP2021519061A5 JP2020551264A JP2020551264A JP2021519061A5 JP 2021519061 A5 JP2021519061 A5 JP 2021519061A5 JP 2020551264 A JP2020551264 A JP 2020551264A JP 2020551264 A JP2020551264 A JP 2020551264A JP 2021519061 A5 JP2021519061 A5 JP 2021519061A5
Authority
JP
Japan
Prior art keywords
cells
induced
cell
genome
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551264A
Other languages
English (en)
Japanese (ja)
Other versions
JP7575271B2 (ja
JP2021519061A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/067289 external-priority patent/WO2019126748A1/en
Application filed filed Critical
Priority claimed from PCT/US2019/024686 external-priority patent/WO2019191495A1/en
Publication of JP2021519061A publication Critical patent/JP2021519061A/ja
Publication of JP2021519061A5 publication Critical patent/JP2021519061A5/ja
Priority to JP2024181460A priority Critical patent/JP2025013853A/ja
Application granted granted Critical
Publication of JP7575271B2 publication Critical patent/JP7575271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551264A 2018-03-29 2019-03-28 操作された免疫エフェクター細胞およびその使用 Active JP7575271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024181460A JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862649781P 2018-03-29 2018-03-29
US62/649,781 2018-03-29
US201862774052P 2018-11-30 2018-11-30
US62/774,052 2018-11-30
USPCT/US2018/067289 2018-12-21
PCT/US2018/067289 WO2019126748A1 (en) 2017-12-22 2018-12-21 Enhanced immune effector cells and use thereof
PCT/US2019/024686 WO2019191495A1 (en) 2018-03-29 2019-03-28 Engineered immune effector cells and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024181460A Division JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2021519061A JP2021519061A (ja) 2021-08-10
JP2021519061A5 true JP2021519061A5 (cg-RX-API-DMAC10.html) 2022-04-04
JP7575271B2 JP7575271B2 (ja) 2024-10-29

Family

ID=68060556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551264A Active JP7575271B2 (ja) 2018-03-29 2019-03-28 操作された免疫エフェクター細胞およびその使用
JP2024181460A Pending JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024181460A Pending JP2025013853A (ja) 2018-03-29 2024-10-17 操作された免疫エフェクター細胞およびその使用

Country Status (13)

Country Link
US (1) US20210024959A1 (cg-RX-API-DMAC10.html)
EP (1) EP3775228B1 (cg-RX-API-DMAC10.html)
JP (2) JP7575271B2 (cg-RX-API-DMAC10.html)
KR (2) KR102817092B1 (cg-RX-API-DMAC10.html)
CN (1) CN111954715A (cg-RX-API-DMAC10.html)
AU (2) AU2019243315A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020019205A2 (cg-RX-API-DMAC10.html)
CA (1) CA3093020A1 (cg-RX-API-DMAC10.html)
ES (1) ES3073987T3 (cg-RX-API-DMAC10.html)
IL (1) IL277611B1 (cg-RX-API-DMAC10.html)
MX (1) MX2020009896A (cg-RX-API-DMAC10.html)
SG (1) SG11202008977UA (cg-RX-API-DMAC10.html)
WO (1) WO2019191495A1 (cg-RX-API-DMAC10.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
CN110628821B (zh) * 2018-06-25 2022-02-18 首都医科大学宣武医院 一种细胞模型及其制备方法、应用
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
BR112021021608A2 (pt) * 2019-04-30 2021-12-21 Atara Biotherapeutics Inc Células car-t direcionadas a cd19 específicas para antígeno
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー,インコーポレイテッド Cd24発現細胞およびそれらの用途
EP4041759A4 (en) * 2019-10-07 2023-12-20 Fate Therapeutics, Inc. IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTIVE CELL ENGINEERING AND ITS USE
EP4045539A4 (en) * 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
CA3179969A1 (en) * 2020-04-09 2021-10-14 Wallkill BioPharma, Inc. Treating autoimmune diseases with genetically modified cells
CA3182286A1 (en) * 2020-05-04 2021-11-11 Editas Medicine, Inc. Selection by essential-gene knock-in
KR20230040337A (ko) * 2020-06-19 2023-03-22 페이트 세러퓨틱스, 인코포레이티드 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
WO2022056489A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
CN114457025A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达btla阻断物的多能干细胞或其衍生物及应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
CN114591950A (zh) * 2020-12-04 2022-06-07 武汉友芝友生物制药股份有限公司 敲除cd38基因的细胞系、其构建方法及应用
CN114107211B (zh) * 2020-12-04 2025-09-30 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
CN114645018A (zh) * 2020-12-18 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达cd38靶向抑制因子的多能干细胞及其衍生物与应用
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN114657137A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向BTLA的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN114657133A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向IL-4 Rα的shRNA和/或shRNA-miR的多能干细胞
KR20230155521A (ko) 2021-03-11 2023-11-10 카이트 파마 인코포레이티드 면역 세포 기능의 향상
US20240254444A1 (en) * 2021-05-04 2024-08-01 Shoreline Biosciences, Inc. Engineered cells for therapy
MX2023014356A (es) * 2021-06-02 2024-02-15 Metagenomi Inc Sistemas crispr de clase ii, tipo v.
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
CN113278652B (zh) * 2021-07-20 2021-10-01 卡瑞济(北京)生命科技有限公司 增加Survivin表达的CAR-T细胞并联合IL-15在制备抗肿瘤药物中的应用
CN122483217A (zh) * 2021-08-06 2026-07-31 上海驯鹿生物技术有限公司 靶向cd7的嵌合抗原受体及其应用
CA3228865A1 (en) * 2021-08-18 2023-02-23 Bahram Valamehr Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
WO2023093763A1 (en) * 2021-11-24 2023-06-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for cell-based immunotherapies cross-reference
WO2023116929A1 (en) * 2021-12-24 2023-06-29 Hemacell Therapeutics Inc. Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination
CN116804185A (zh) * 2022-03-25 2023-09-26 士泽生物医药(苏州)有限公司 一种通用型细胞及其制备方法
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
CA3252595A1 (en) 2022-05-25 2023-11-30 Metagenomi Therapeutics, Inc. LIVER ENZYME EXPRESSION SUPPLEMENTATION
CN116716342A (zh) * 2022-06-22 2023-09-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
CN120359048A (zh) * 2022-09-02 2025-07-22 美洛德生物医药公司 用于细胞特异性表达的组合物及其用途
GB2639327A (en) * 2022-09-22 2025-09-24 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
WO2024102704A2 (en) * 2022-11-07 2024-05-16 Fate Therapeutics, Inc. Ipsc-derived nk cell targeting mica/b for solid tumor treatment
WO2024183750A1 (en) * 2023-03-07 2024-09-12 Qihan Hong Kong Limited A novel immune cell and use thereof for treating diseases
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
CN116286905B (zh) * 2023-05-11 2023-08-15 内蒙古大学 牛源化CRISPR/boCas9基因编辑系统、方法及应用
WO2025031500A1 (zh) * 2023-08-10 2025-02-13 深圳市三启生物技术有限公司 含有gprc5d抗体的嵌合抗原受体及其应用
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2025102504A1 (zh) * 2023-11-15 2025-05-22 复旦大学 基于i型内含子的环状rna制备方法及其应用
WO2025240349A2 (en) * 2024-05-15 2025-11-20 Be Biopharma, Inc. Allogeneic cell compositions and methods thereof
WO2025257119A1 (en) * 2024-06-10 2025-12-18 Repairon Immuno Gmbh Method of producing a modified immune cell from a pluripotent stem cell (psc)
CN119264271B (zh) * 2024-10-08 2025-05-09 北京市神经外科研究所 一种nk细胞特异性的嵌合抗原受体及其应用
CN121159717B (zh) * 2025-09-11 2026-04-21 中邦干细胞科技有限公司 一种嵌合蛋白、工程化nk细胞及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5766944A (en) * 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
CN113699159A (zh) 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
US10738278B2 (en) * 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CA3007473A1 (en) 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas

Similar Documents

Publication Publication Date Title
JP2022550899A5 (cg-RX-API-DMAC10.html)
JP2022527405A5 (cg-RX-API-DMAC10.html)
JP2022548943A5 (cg-RX-API-DMAC10.html)
JP2022541441A5 (cg-RX-API-DMAC10.html)
JP2021505131A5 (cg-RX-API-DMAC10.html)
JP2022510207A5 (cg-RX-API-DMAC10.html)
JP2023548467A5 (cg-RX-API-DMAC10.html)
JP2023549098A5 (cg-RX-API-DMAC10.html)
JP2023530704A5 (cg-RX-API-DMAC10.html)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
Lipowska-Bhalla et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
JP2023548829A5 (cg-RX-API-DMAC10.html)
US11896620B2 (en) Engineered immune cell and use thereof
EP4166655A1 (en) Engineered immune cell and use thereof
US10925943B2 (en) Marker-suicide gene useful in adoptive cell therapy
JP2024518011A5 (cg-RX-API-DMAC10.html)
CN112029001A (zh) 靶向nk激活性受体的嵌合抗原受体
JP2023545992A5 (cg-RX-API-DMAC10.html)
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
JP2022531222A5 (cg-RX-API-DMAC10.html)
JP2022552314A5 (cg-RX-API-DMAC10.html)
CA3078270A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2018522567A (ja) 固形腫瘍を標的とする二重特異性car t細胞
JP2017512054A (ja) 三官能性t細胞−抗原カプラ及び方法並びにこれらの使用
US20240009308A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof